Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00965627
Other study ID # ONC/OSS-01/2008
Secondary ID
Status Completed
Phase N/A
First received August 6, 2009
Last updated August 27, 2009
Start date June 2008
Est. completion date August 2009

Study information

Verified date August 2009
Source Istituto Clinico Humanitas
Contact n/a
Is FDA regulated No
Health authority Italy: Ministry of Health
Study type Observational

Clinical Trial Summary

This is a retrospective analysis of biological characteristics of thymoma and thymic carcinoma patients.


Description:

The aim of the present study is to investigated the genetic alterations in tumor samples of a series of all WHO-defined subtypes of thymoma patients using high resolution microarray- comparative genomic hybridization (CGH) followed by hierarchical cluster analyses of the data to identify specific patterns of genetic aberrations and genes associated with each subtype. Moreover, tumor samples will be also investigated for some specific potential therapy targets by immunoistichemistry, mutation analysis, and fluorescence in situ hybridization (FISH) analysis. All these biological data will be correlated with clinical patients characteristics and survival data.


Recruitment information / eligibility

Status Completed
Enrollment 134
Est. completion date August 2009
Est. primary completion date August 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Availability of tumor tissue and patients with thymoma and thymic carcinoma

Exclusion Criteria:

- NON Availability of tumor tissue and patients with thymoma and thymic carcinoma

Study Design

Observational Model: Cohort, Time Perspective: Retrospective


Related Conditions & MeSH terms


Locations

Country Name City State
Italy Istituto Clinico Humanitas Rozzano Milano

Sponsors (1)

Lead Sponsor Collaborator
Istituto Clinico Humanitas

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary objective: to evaluate the presence of genetic alterations and specific potential therapy targets. one year No
Secondary Secondary objective: to correlate the biological characteristics with clinical characteristics and survival data of patients. one year No
See also
  Status Clinical Trial Phase
Recruiting NCT01950572 - Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Terminated NCT00818090 - Paclitaxel and Cisplatin for Thymic Neoplasm Phase 2
Completed NCT00332969 - Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma Phase 2
Completed NCT00921739 - Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies Phase 1
Recruiting NCT05255965 - IL-8+ naïve T Cells as a Biomarker for Thymoma Identification
Withdrawn NCT02948855 - Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases
Completed NCT00387868 - Preoperative Treatment of Patients With High Risk Thymoma Phase 2
Completed NCT01272817 - Nonmyeloablative Allogeneic Transplant N/A
Recruiting NCT03466827 - Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma Phase 2
Completed NCT02220855 - A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas Phase 2
Completed NCT03288662 - Relationship Between Computed Tomography Manifestation and Histopathological Classification of Thymic Epithelial Tumors N/A
Active, not recruiting NCT01242072 - Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies Phase 1
Recruiting NCT06029621 - Robot-assisted vs VATS for Thymoma N/A
Active, not recruiting NCT03921671 - Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT) Phase 2
Active, not recruiting NCT01621568 - Sunitinib for Advanced Thymus Cancer Following Earlier Treatment Phase 2
Recruiting NCT05262582 - Comparison of Single Port and Two Ports Robotic Assisted Thoracic Surgery for Thymectomy N/A
Terminated NCT01100944 - A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies Phase 1/Phase 2
Active, not recruiting NCT03968315 - An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent Thymoma N/A
Recruiting NCT04162691 - Single Cell Sequencing Analysis of Thymoma
Recruiting NCT06086327 - Application of 68Ga-Pentixafor PET/CT for Thymoma Early Phase 1